The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Review: IL-6 Transsignaling: The In Vivo Consequences
Abstract
Cytokine receptors exist in membrane-bound and soluble forms. They bind their ligands with comparable affinity. Although most soluble receptors are antagonists because they compete with their membrane counterparts for their ligands, some soluble receptors are agonists. In this case, on target cells, the complex of cytokine and soluble cytokine receptor binds to a second receptor subunit and initiates intracellular signal transduction. The soluble receptors of the interleukin-6 (IL-6) family of cytokines--soluble IL-6 receptor (sIL-6R), sIL-11R, and soluble ciliary neurotrophic factor receptor (sCNTFR)--are agonists. In vivo, the IL-6/sIL-6R complex stimulates several types of target cells not stimulated by IL-6 alone, as they do not express the membrane- bound IL-6R. This process has been named transsignaling. We have shown recently that in several chronic inflammatory diseases, such as chronic inflammatory bowl disease, peritonitis, and rheumatoid arthritis, as well as in colon cancer, transsignaling via the sIL-6R complexed to IL-6 is a crucial point in the maintenance of the disease. The mechanism by which the IL-6/sIL-6R complex regulates the inflammatory or neoplastic state is discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130
Taga, T., Hibi, M., Hirata, Y., Yamasaki, K., Yasukawa, K., Matsuda, T., Hirano, T., & Kishimoto, T. (1989) · Cell · doi:10.1016/0092-8674(89)90438-8 · Cited by 1,396
Atreya, R., Mudter, J., Finotto, S., Müllberg, J., Jostock, T., Wirtz, S., Schütz, M., Bartsch, B., Holtmann, M., Becker, C., et al. (2000) · Nature Medicine · doi:10.1038/75068 · Cited by 1,293
Self-citationSubpopulations of Mouse Blood Monocytes Differ in Maturation Stage and Inflammatory Response
Sunderkötter, C., Nikolic, T., Dillon, M. J., van Rooijen, N., Stehling, M., Drevets, D. A., & Leenen, P. J. M. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.7.4410 · Cited by 1,124
Schindler, R., Mancilla, J., Endres, S., Ghorbani, R., Clark, S., & Dinarello, C. (1990) · Blood · doi:10.1182/blood.v75.1.40.40 · Cited by 1,012
SOCS3 negatively regulates IL-6 signaling in vivo
Croker, B. A., Krebs, D. L., Zhang, J.-G., Wormald, S., Willson, T. A., Stanley, E. G., Robb, L., Greenhalgh, C. J., Förster, I., Clausen, B. E., et al. (2003) · Nature Immunology · doi:10.1038/ni931 · Cited by 840
IL-6: a regulator of the transition from neutrophil to monocyte recruitment during inflammation
Kaplanski, G. (2003) · Trends in Immunology · doi:10.1016/s1471-4906(02)00013-3 · Cited by 811
Hurst, S. M., Wilkinson, T. S., McLoughlin, R. M., Jones, S., Horiuchi, S., Yamamoto, N., Rose-John, S., Fuller, G. M., Topley, N., & Jones, S. A. (2001) · Immunity · doi:10.1016/s1074-7613(01)00151-0 · Cited by 811
Self-citationIto, H., Takazoe, M., Fukuda, Y., Hibi, T., Kusugami, K., Andoh, A., Matsumoto, T., Yamamura, T., Azuma, J., & Nishimoto, N. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.01.012 · Cited by 636
Takeda, K., Kaisho, T., Yoshida, N., Takeda, J., Kishimoto, T., & Akira, S. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.9.4652 · Cited by 584
Choy, E. H. S., Isenberg, D. A., Garrood, T., Farrow, S., Ioannou, Y., Bird, H., Cheung, N., Williams, B., Hazleman, B., Price, R., et al. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10623 · Cited by 526
Cited by
McGonagle, D., Sharif, K., O'Regan, A., & Bridgewood, C. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102537 · Cited by 1,654
Immune modulation of learning, memory, neural plasticity and neurogenesis
Yirmiya, R., & Goshen, I. (2011) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2010.10.015 · Cited by 1,483
Besedovsky, L., Lange, T., & Born, J. (2012) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-011-1044-0 · Cited by 1,153
Directing Transition from Innate to Acquired Immunity: Defining a Role for IL-6
Jones, S. A. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.6.3463 · Cited by 771
Self-citationNeutrophil function in inflammation and inflammatory diseases
Wright, H. L., Moots, R. J., Bucknall, R. C., & Edwards, S. W. (2010) · Rheumatology · doi:10.1093/rheumatology/keq045 · Cited by 761
Interleukin-6 in Aging and Chronic Disease: A Magnificent Pathway
Maggio, M., Guralnik, J. M., Longo, D. L., & Ferrucci, L. (2006) · The Journals of Gerontology: Series A · doi:10.1093/gerona/61.6.575 · Cited by 692
Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling
Jones, S. A., Scheller, J., & Rose-John, S. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57158 · Cited by 683
Self-citationTargeting interleukin-6 in inflammatory autoimmune diseases and cancers
Yao, X., Huang, J., Zhong, H., Shen, N., Faggioni, R., Fung, M., & Yao, Y. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.09.004 · Cited by 664
Rose-John, S., Scheller, J., Elson, G., & Jones, S. A. (2006) · Journal of Leukocyte Biology · doi:10.1189/jlb.1105674 · Cited by 647
Self-citationCOVID-19 infection: an overview on cytokine storm and related interventions
Montazersaheb, S., Hosseiniyan Khatibi, S. M., Hejazi, M. S., Tarhriz, V., Farjami, A., Ghasemian Sorbeni, F., Farahzadi, R., & Ghasemnejad, T. (2022) · Virology Journal · doi:10.1186/s12985-022-01814-1 · Cited by 610
The nuclear factor- B-interleukin-6 signalling pathway mediating vascular inflammation
Brasier, A. R. (2010) · Cardiovascular Research · doi:10.1093/cvr/cvq076 · Cited by 586
IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer
Neurath, M. F., & Finotto, S. (2011) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2011.02.003 · Cited by 576
Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage
Grivennikov, S. I., & Karin, M. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.140145 · Cited by 560
The interferons and their receptors—distribution and regulation
de Weerd, N. A., & Nguyen, T. (2012) · Immunology & Cell Biology · doi:10.1038/icb.2012.9 · Cited by 480
Noncoding RNAs, cytokines, and inflammation-related diseases
Marques-Rocha, J. L., Samblas, M., Milagro, F. I., Bressan, J., Martínez, J. A., & Marti, A. (2015) · The FASEB Journal · doi:10.1096/fj.14-260323 · Cited by 477
Il-6 signaling in inflammatory bowel disease: Pathophysiological role and clinical relevance
Mudter, J., & Neurath, M. F. (2007) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20148 · Cited by 436
Versatile functions for IL-6 in metabolism and cancer
Mauer, J., Denson, J. L., & Brüning, J. C. (2015) · Trends in Immunology · doi:10.1016/j.it.2014.12.008 · Cited by 407
Inflammatory Biomarkers for Persistent Fatigue in Breast Cancer Survivors
Collado-Hidalgo, A., Bower, J. E., Ganz, P. A., Cole, S. W., & Irwin, M. R. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2398 · Cited by 394
Type I Interferon Receptors: Biochemistry and Biological Functions
de Weerd, N. A., Samarajiwa, S. A., & Hertzog, P. J. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.r700006200 · Cited by 390
The role of Interleukin 6 in the pathophysiology of rheumatoid arthritis
Srirangan, S., & Choy, E. H. (2010) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x10378372 · Cited by 357
The varying faces of IL-6: From cardiac protection to cardiac failure
Fontes, J. A., Rose, N. R., & Čiháková, D. (2015) · Cytokine · doi:10.1016/j.cyto.2014.12.024 · Cited by 337
The IL-6/JAK/STAT3 pathway: Potential therapeutic strategies in treating colorectal cancer
WANG, S.-W., & SUN, Y.-M. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2259 · Cited by 320
Nociceptive neurons detect cytokines in arthritis
Schaible, H.-G. (2014) · Arthritis Research & Therapy · doi:10.1186/s13075-014-0470-8 · Cited by 319
Interleukin‐6 Trans‐Signalling in Chronic Inflammation and Cancer
Scheller, J., Ohnesorge, N., & Rose‐John, S. (2006) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.2006.01750.x · Cited by 297
Self-citationHow much is too much? Interleukin-6 and its signalling in atherosclerosis
Schuett, H., Luchtefeld, M., Grothusen, C., Grote, K., & Schieffer, B. (2009) · Thrombosis and Haemostasis · doi:10.1160/th09-05-0297 · Cited by 289
IL-6 trans-signaling promotes pancreatitis-associated lung injury and lethality
Zhang, H., Neuhöfer, P., Song, L., Rabe, B., Lesina, M., Kurkowski, M. U., Treiber, M., Wartmann, T., Regnér, S., Thorlacius, H., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci64931 · Cited by 288
Self-citationTherapeutic targets in rheumatoid arthritis: the interleukin-6 receptor
Dayer, J.-M., & Choy, E. (2010) · Rheumatology · doi:10.1093/rheumatology/kep329 · Cited by 267
IL-6 Trans-Signaling Modulates TLR4-Dependent Inflammatory Responses via STAT3
Greenhill, C. J., Rose-John, S., Lissilaa, R., Ferlin, W., Ernst, M., Hertzog, P. J., Mansell, A., & Jenkins, B. J. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1002971 · Cited by 264
Self-citationDifferences in Wound Healing in Mice with Deficiency of IL-6 versus IL-6 Receptor
McFarland-Mancini, M. M., Funk, H. M., Paluch, A. M., Zhou, M., Giridhar, P. V., Mercer, C. A., Kozma, S. C., & Drew, A. F. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0901929 · Cited by 249
Interleukin‐6 promotes tumorigenesis by altering DNA methylation in oral cancer cells
Gasche, J. A., Hoffmann, J., Boland, C. R., & Goel, A. (2011) · International Journal of Cancer · doi:10.1002/ijc.25764 · Cited by 178
Hartman, Z. C., Yang, X.-Y., Glass, O., Lei, G., Osada, T., Dave, S. S., Morse, M. A., Clay, T. M., & Lyerly, H. K. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0308 · Cited by 137
“For instance, the presence of high levels of soluble IL-6Ra in vivo (36) could permit IL-6 trans signaling in tumor cells, as IL-6Ra could be a limiting activating factor in certain cell types.”
BackgroundIL‐6 Trans‐signaling Controls Liver Regeneration After Partial Hepatectomy
Fazel Modares, N., Polz, R., Haghighi, F., Lamertz, L., Behnke, K., Zhuang, Y., Kordes, C., Häussinger, D., Sorg, U. R., Pfeffer, K., et al. (2019) · Hepatology · doi:10.1002/hep.30774 · Cited by 113
Self-citationSleep enhances IL‐6 trans‐signaling in humans
Dimitrov, S., Lange, T., Benedict, C., Nowell, M. A., Jones, S. A., Scheller, J., Rose‐John, S., Born, J., Dimitrov, S., Lange, T., et al. (2006) · The FASEB Journal · doi:10.1096/fj.06-5754fje · Cited by 115
Self-citationImpact of interleukin-6 classic- and trans-signaling on liver damage and regeneration
Drucker, C., Gewiese, J., Malchow, S., Scheller, J., & Rose-John, S. (2010) · Journal of Autoimmunity · doi:10.1016/j.jaut.2009.08.003 · Cited by 83
Self-citation
Metadata
- Authors
- Jones, S. A., Richards, P. J., Scheller, J., & Rose-John, S.
- Venue
- Journal of Interferon & Cytokine Research
- Publisher
- SAGE Publications
- Published
- 2005-05
- Volume
- 25
- Issue
- 5
- Pages
- 241-253
- ISSN
- 1079-9907 (ISSN-L)
- 1557-7465
- OpenAlex
- W2406295010
- Cited by
- 251
- References
- 19
- FWCI
- 7.63
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.